Bifogade filer
PDF
Kurs
-3,89%
Likviditet
0,12 MSEK
Kalender
| Tid* | ||
| 2025-02-14 | 08:00 | Bokslutskommuniké 2024 |
| 2024-11-29 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-30 | - | Kvartalsrapport 2024-Q2 |
| 2024-07-08 | - | Split APTA 100:1 |
| 2024-06-19 | - | Extra Bolagsstämma 2024 |
| 2024-05-31 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-17 | - | X-dag ordinarie utdelning APTA 0.00 SEK |
| 2024-05-15 | - | Årsstämma |
| 2024-02-29 | - | Bokslutskommuniké 2023 |
| 2024-01-09 | - | Extra Bolagsstämma 2023 |
| 2023-10-30 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-31 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-02 | - | X-dag ordinarie utdelning APTA 0.00 SEK |
| 2023-06-01 | - | Årsstämma |
| 2023-05-11 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-15 | - | Bokslutskommuniké 2022 |
| 2022-11-08 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-03 | - | X-dag ordinarie utdelning APTA 0.00 SEK |
| 2022-06-02 | - | Årsstämma |
| 2022-05-19 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-10 | - | Bokslutskommuniké 2021 |
| 2021-11-11 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-03 | - | X-dag ordinarie utdelning APTA 0.00 SEK |
| 2021-06-02 | - | Årsstämma |
| 2021-05-20 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-30 | - | Kvartalsrapport 2020-Q3 |
| 2020-09-25 | - | Extra Bolagsstämma 2020 |
| 2020-08-26 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-04 | - | X-dag ordinarie utdelning APTA 0.00 SEK |
| 2020-06-03 | - | Årsstämma |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-12 | - | Bokslutskommuniké 2019 |
| 2019-10-24 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-28 | - | Kvartalsrapport 2019-Q2 |
| 2019-06-12 | - | X-dag ordinarie utdelning APTA 0.00 SEK |
| 2019-06-11 | - | Årsstämma |
| 2019-05-15 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-08-29 | - | Kvartalsrapport 2018-Q2 |
| 2018-06-07 | - | Extra Bolagsstämma 2018 |
| 2018-05-07 | - | Årsstämma |
| 2018-05-07 | - | X-dag ordinarie utdelning APTA 0.00 SEK |
| 2018-05-03 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-15 | - | Bokslutskommuniké 2017 |
| 2017-11-15 | - | Kvartalsrapport 2017-Q3 |
| 2017-09-11 | - | Extra Bolagsstämma 2017 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-06-08 | - | X-dag ordinarie utdelning APTA 0.00 SEK |
| 2017-06-07 | - | Årsstämma |
| 2017-05-18 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-16 | - | Bokslutskommuniké 2016 |
| 2016-10-27 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-20 | - | Kvartalsrapport 2016-Q2 |
| 2016-06-09 | - | Årsstämma |
| 2016-05-19 | - | X-dag ordinarie utdelning APTA 0.00 SEK |
| 2016-05-18 | - | Kvartalsrapport 2016-Q1 |
| 2016-03-22 | - | Extra Bolagsstämma 2016 |
| 2016-02-18 | - | Bokslutskommuniké 2015 |
| 2015-10-29 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-20 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-18 | - | Årsstämma |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Aptahem (publ) announces today that Ingela Hallberg has been appointed new Chief Medical Officer (CMO) in the company as of 1 June 2022. Ingela has long and solid experience from the pharmaceutical industry where she has held senior management positions within clinical research and development and medical affairs in a number of companies, both in regional and global roles, and within several different therapy areas. Four years ago she started her own company to support start-ups within life science to develop their products. Ingela is a medical doctor and previously worked within the area of cardiology, Sahlgrenska University Hospital, Gothenburg.
Ingela replaces Anders Bylock, who due to time limitations, can't cover the increased activities required when Aptahem becomes a clinical company. Anders has been the company's CMO since 2018 and is also, since 2017, chairman of the scientific advisory board. In connection with Ingela being appointed new CMO, Aptahem initiates the process in reviewing the scientific advisory board. The purpose is to broaden the advisory board to include more than scientific areas.
CMO Ingela Hallberg comments:
"Aptahem's development project within sepsis is very interesting and I am looking forward to contributing with my broad medical experience from various therapy areas. I have for many years worked with development projects in global pharmaceutical companies and see Apta-1 as a very exciting and innovative drug candidate. Its unique mechanism of action makes it well suited to be tested as a future treatment for various serious inflammatory conditions, where sepsis will be an interesting first indication."
CEO Mikael Lindstam comments:
"With Ingela as CMO, Aptahem gets an experienced leader who will focus on taking Aptahem into clinical phase. Her background from senior management positions in various global pharmaceutical companies provides valuable addition, as well as her broad experience from development projects within different therapy areas. I also want to thank Anders for his valuable contribution during the years, both as CMO and as scientific advisor."
For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com
About Aptahem
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company's primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.